This page shows the latest insulin aspart news and features for those working in and with pharma, biotech and healthcare.
The Danish drugmaker says it will offer an authorised generic version of NovoLog (insulin aspart) at around $145 per vial, roughly half the branded drug’s current US list price, from ... which offered a 50% cheaper version of its Humalog (insulin lispro
10% gain for Tresiba (insulin degludec) and a sharp increase for Xultophy, a combination insulin/GLP-1 shot which more than doubled to 1.6bn krone. ... Novo’s CEO Lars Fruergaard Jørgensen. New fast-acting mealtime insulin Fiasp (insulin aspart),
The dual-therapy works to reduce high blood glucose while enhancing glucose-dependent insulin secretion and reducing glucagon release. ... Meanwhile, Novo Nordisk looks set to add Fiasp (insulin aspart) to its diabetes drug stable, as the fast-acting
Sales of Novo Nordisk's new basal insulin product Tresiba have started to gather momentum since its US launch in January, rising three-fold in the first half of the year. ... Nevertheless, the strong sales performance for Tresiba and other new insulin
Moreover, it could also differentiate Tresiba from biosimilar copies of Sanofi's drug that are starting to reach the market and threaten to disrupt the basal insulin category. ... Last October however the Danish drugmaker finally won US approval for
Long-acting basal insulin Tresiba (insulin degludec) and combination drug Ryzodeg (insulin degludec and insulin aspart) will now be able to compete head-to-head in the market with Sanofi's ... that the drug – along with Ryzodeg and Xultophy (insulin
More from news
Approximately 2 fully matching, plus 21 partially matching documents found.
Dice Medical Communications is an independent communications agency that works with our clients to help launch, build, and continually develop...